Redwood Pharma takes important steps towards the commercial production of its dry eye product
Stockholm, 24 January 2023. Redwood Pharma AB (publ) announces that the company has completed further preparations for the scale-up of production of the company's medical technology product RP501, which is being developed as a treatment for dry eye. As part of the preparations, Redwood Pharma has invested in equipment at the company's manufacturing partner.During 2022, Redwood Pharma has worked to optimize the process and produce a technical production batch of RP501. Once the new equipment has been installed at the contract manufacturer, the company can proceed with adapting the production